EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy

Yi Zhu, Jiawei Song, Yansheng Zhu, Haiyi Xu, Shanshan Lang, Xulu Yang, Yanxiang Zhang, Teng Liu iD

Advanced Materials · 2026-03 · 38 (14)

DOI: 10.1002/adma.202517019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 02.02.2026. Verfasst von Yi Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinar…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms, Programmed Cell Death 1 Receptor, Biocompatible Materials. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 193 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Research and Development Program of Social Development of Jiangsu Province, Natural Science Foundation of the Jiangsu Higher Education Institutions of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional monoclonal antibodies targeting either PD‐1 or PD‐L1, despite the clinical significance as immune checkpoint inhibitors (ICIs), exhibit limited effect in the majority of cancer patients. The persistent challenges in ICIs have prompted extensive research into next‐generation biomaterial‐based immunotherapeutic strategies to inhibit PD‐1/PD‐L1 pathway. Herein, this review started with the retrospect of recent insights into the dynamic regulation of PD‐L1 expression patterns and its multifaceted functional mechanisms within the tumor microenvironment. Subsequently, the emerging alternatives to PD‐1/PD‐L1 inhibitors are summarized by their categories, including peptides, nucleic acids, small molecule inhibitors, and natural compounds, which could function by reducing PD‐L1 expression, degrading PD‐L1, or inhibiting PD‐1/PD‐L1 interactions. Furthermore, recent efforts on combination therapy based on these biomaterials are discussed, especially those with chemotherapy, radiotherapy, phototherapy, and sonodynamic therapy. This paradigm shift in PD‐1/PD‐L1 immune checkpoint blockade therapy underscores the prospects of emerging biomaterials in orchestrating anticancer immune responses, which would provide insights for developing next‐generation immunotherapeutic strategies for clinical oncology to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsProgrammed Cell Death 1 ReceptorBiocompatible MaterialsImmune Checkpoint InhibitorsHumansAnimalsImmunotherapyTumor MicroenvironmentSignal Transduction

Stichwörter der Autor:innen

PD‐1/PD‐L1biomaterialscancer therapycombination therapyimmune checkpoint blockade

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorBiocompatible MaterialsImmune Checkpoint InhibitorsCD274 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medic…

ORCID-Profile: Teng Liu

Förderung

  • National Natural Science Foundation of China
  • Research and Development Program of Social Development of Jiangsu Province
  • Natural Science Foundation of the Jiangsu Higher Education Institutions of China
  • Suzhou Fundamental Research Project
  • Interdisciplinary Basic Frontier Innovation Program of Suzhou Medical College of Soochow University
  • College Students' Innovative Entrepreneurial Training Plan Program

Zitieren

APA

Zhu, Y., Song, J., Zhu, Y., Xu, H., Lang, S., Yang, X., Zhang, Y., & Liu, T. (2026). Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy. Advanced Materials, 38(14). https://doi.org/10.1002/adma.202517019

Vancouver

Zhu Y, Song J, Zhu Y, Xu H, Lang S, Yang X, et al. Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy. Advanced Materials. 2026;38(14). doi:10.1002/adma.202517019

BibTeX
@article{Zhu2026,
  author = {Zhu, Yi and Song, Jiawei and Zhu, Yansheng and Xu, Haiyi and Lang, Shanshan and Yang, Xulu and Zhang, Yanxiang and Liu, Teng},
  title = {Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {14},
  doi = {10.1002/adma.202517019}
}
Kostenlos starten →